Spectrum Pharmaceuticals (SPPI)
Add to Watchlists Create an Alert
8.55
+0.12 +1.42%
NASDAQ
May 23, 4:58PM
BATS Real time
Currency in USD
Spectrum Pharmaceuticals Revenue Quarterly YoY Growth:
32.32% for Dec. 31, 2012Spectrum Pharmaceuticals Historical Revenue Quarterly YoY Growth Data
Pro Data Export
Dates:
to
There is no data for the selected date range.
| Data for this Date Range | |
|---|---|
| Dec. 31, 2012 | 32.32% |
| Sept. 30, 2012 | 35.31% |
| June 30, 2012 | 51.45% |
| March 31, 2012 | 37.30% |
| Dec. 31, 2011 | 56.07% |
| Sept. 30, 2011 | 204.9% |
| June 30, 2011 | 267.5% |
| March 31, 2011 | 293.2% |
| Dec. 31, 2010 | 293.8% |
| Sept. 30, 2010 | 135.7% |
| June 30, 2010 | 51.62% |
| March 31, 2010 | -21.70% |
| Dec. 31, 2009 | 7.09% |
| Sept. 30, 2009 | |
| June 30, 2009 | -60.63% |
| March 31, 2009 | |
| Dec. 31, 2008 | 17026% |
| Sept. 30, 2008 | |
| June 30, 2008 | 412.8% |
| March 31, 2008 | Go Pro |
| Dec. 31, 2007 | Go Pro |
| Sept. 30, 2007 | Go Pro |
| June 30, 2007 | Go Pro |
| March 31, 2007 | Go Pro |
| Dec. 31, 2006 | Go Pro |
| Sept. 30, 2006 | Go Pro |
| June 30, 2006 | Go Pro |
| March 31, 2006 | Go Pro |
| Dec. 31, 2005 | Go Pro |
| Sept. 30, 2005 | Go Pro |
| June 30, 2005 | Go Pro |
| March 31, 2005 | Go Pro |
| Dec. 31, 2004 | Go Pro |
| Sept. 30, 2004 | Go Pro |
| June 30, 2004 | Go Pro |
| March 31, 2004 | Go Pro |
| Dec. 31, 2003 | Go Pro |
| Sept. 30, 2003 | Go Pro |
| June 30, 2003 | Go Pro |
| March 31, 2003 | Go Pro |
| Dec. 31, 2002 | Go Pro |
| Sept. 30, 2002 | Go Pro |
| June 30, 2002 | Go Pro |
| March 31, 2002 | Go Pro |
| Dec. 31, 2001 | Go Pro |
| Sept. 30, 2001 | Go Pro |
| June 30, 2001 | Go Pro |
| March 31, 2001 | Go Pro |
| Dec. 31, 2000 | Go Pro |
| Sept. 30, 2000 | Go Pro |
About Revenue Growth
Revenue growth illustrates sales increases/decreases over time. It is used to measure how fast a business is expanding. More valuable than a snapshot of revenue, revenue growth helps investors identify trends in order to gauge revenue growth over time.
If a company generated $75 billion in revenue during 2008 and $100 billion in revenue during 2009, the company experienced roughly a ($100 billion/$75 billion)-1 = %33 increase in revenue.
Learn More
SPPI Revenue Quarterly YoY Growth Benchmarks
| Companies | |
|---|---|
| Elan | 0.00% |
| Agenus | -91.71% |
| Biocryst Pharmaceuticals | -70.92% |
SPPI Revenue Quarterly YoY Growth Rankings
| Overall |
92nd percentile 616 of 8006 |
| Sector |
85th percentile 101 of 686 in Healthcare |
| Industry |
80th percentile 48 of 248 in Biotechnology |
SPPI Revenue Quarterly YoY Growth Range, Past 5 Years
| Minimum | -60.63% | Jun 2009 |
| Maximum | 17026% | Dec 2008 |
| Average | 1176% |